PTO- 1581 |
Approved for use through 12/31/2020. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Input Field |
Entered |
SERIAL NUMBER | 88056364 |
---|---|
LAW OFFICE ASSIGNED | LAW OFFICE 117 |
MARK SECTION | |
MARK | BASILEA LABS (see, http://uspto.report/TM/88056364/mark.png) |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | BASILEA LABS |
OWNER SECTION (current) | |
NAME | Basilea Pharmaceutica AG |
MAILING ADDRESS | Grenzacherstrasse 487 |
CITY | Basel |
ZIP/POSTAL CODE | 4058 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Switzerland |
XXXX | |
OWNER SECTION (proposed) | |
NAME | Basilea Pharmaceutica AG |
MAILING ADDRESS | Grenzacherstrasse 487 |
CITY | Basel |
ZIP/POSTAL CODE | 4058 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Switzerland |
XXXX | |
CORRESPONDENCE INFORMATION (current) | |
NAME | Evan A. Raynes |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | eraynes@symbus.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | legalasst@symbus.com |
CORRESPONDENCE INFORMATION (proposed) | |
NAME | Evan A. Raynes |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | eraynes@symbus.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | kflanagan@symbus.com |
GOODS AND/OR SERVICES SECTION | |
INTERNATIONAL CLASS | 001 |
CURRENT IDENTIFICATION | Diagnostic preparations for clinical or medical laboratory use; Diagnostic reagents for clinical or medical laboratory use |
GOODS OR SERVICES | KEEP ALL LISTED |
INTERNATIONAL CLASS | 005 |
CURRENT IDENTIFICATION | Pharmaceutical and veterinary preparations for the treatment or prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary preparations for the treatment of infections caused by bacteria, fungi, viruses and rheumatoid arthritis; Pharmaceutical and veterinary preparations for the treatment of diseases, disorders and conditions in the area of oncology |
GOODS OR SERVICES | KEEP ALL LISTED |
EXTENSION SECTION | |
EXTENSION NUMBER | 3 |
ONGOING EFFORT | product or service research or development |
ALLOWANCE MAIL DATE | 09/03/2019 |
STATEMENT OF USE | NO |
PAYMENT SECTION | |
NUMBER OF CLASSES | 2 |
SUBTOTAL AMOUNT [EXTENSION FEE] | 250 |
TOTAL AMOUNT | 250 |
SIGNATURE SECTION | |
SIGNATURE | /Evan A. Raynes/ |
SIGNATORY'S NAME | Evan A. Raynes |
SIGNATORY'S POSITION | Attorney of record, DC bar member |
DATE SIGNED | 02/12/2021 |
SIGNATORY'S PHONE NUMBER | 202-258-0652 |
SIGNATURE METHOD | Signed directly within the form |
FILING INFORMATION | |
SUBMIT DATE | Fri Feb 12 18:12:08 ET 2021 |
TEAS STAMP | USPTO/ESU-XXX.XX.XXX.XX-2 0210212181208433580-88056 364-760aa1fed5550f29ff6b4 d47f44b88843c6fd629c10199 a81165de9c586f06b79-CC-12 054997-202102121810024192 37 |
PTO- 1581 |
Approved for use through 12/31/2020. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |